GNLX (Genelux Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by GNLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Yong Yu | Chief Scientific Officer | Sell | — | — |
| 2026-09-02 | Thomas Zindrick | President and CEO | Sell | — | — |
| 2026-09-02 | Joseph Cappello | Chief Technical Officer | Sell | — | — |
| 2026-08-04 | Yong Yu | Chief Scientific Officer | Sell | — | — |
| 2026-08-04 | Thomas Zindrick | President and CEO | Sell | — | — |
| 2026-08-04 | Joseph Cappello | Chief Technical Officer | Sell | — | — |
| 2026-07-02 | John W Smither | Director | Sell | — | — |
| 2026-06-18 | Thomas Zindrick | President and CEO | A | — | — |
| 2026-06-18 | John Thomas | Director | A | — | — |
| 2026-06-18 | Eric Groen | General Counsel | A | — | — |
| 2026-06-18 | Matthew Pulisic | Chief Financial Officer | A | — | — |
| 2026-06-18 | Joseph Cappello | Chief Technical Officer | A | — | — |
| 2026-06-18 | James L Tyree | Director | A | — | — |
| 2026-06-18 | Mary Mirabelli | Director | A | — | — |
| 2026-06-18 | Yong Yu | Chief Scientific Officer | A | — | — |
| 2026-06-18 | John W Smither | Director | A | — | — |
| 2026-06-04 | Ralph Smalling | Head of Regulatory | Sell | — | — |
| 2026-06-02 | John Thomas | Director | Sell | — | — |
| 2026-05-12 | Ralph Smalling | Head of Regulatory | Sell | — | — |
| 2026-05-12 | Yong Yu | Chief Scientific Officer | Sell | — | — |
| 2026-05-12 | Thomas Zindrick | President and CEO | Sell | — | — |
| 2026-05-12 | Joseph Cappello | Chief Technical Officer | Sell | — | — |
| 2026-03-26 | Yong Yu | SVP, Clinical Development | Sell | — | — |
| 2026-03-26 | Thomas Zindrick | President and CEO | Sell | — | — |
| 2026-03-26 | Ralph Smalling | Head of Regulatory | Sell | — | — |
| 2026-03-26 | Joseph Cappello | Chief Technical Officer | Sell | — | — |
| 2026-03-03 | John Thomas | Director | Sell | — | — |
| 2026-01-07 | Jason Litten | Chief Medical Officer | A | — | — |
| 2025-12-11 | Thomas Zindrick | President and CEO | Sell | — | — |
| 2025-12-11 | Joseph Cappello | Chief Technical Officer | Sell | — | — |
| 2025-12-11 | Yong Yu | SVP, Clinical Development | Sell | — | — |
| 2025-12-09 | Ralph Smalling | Head of Regulatory | Sell | — | — |
| 2025-12-02 | John Thomas | Director | Sell | — | — |
| 2025-09-03 | Yong Yu | SVP, Clinical Development | MIXED | — | — |
| 2025-09-03 | Joseph Cappello | Chief Technical Officer | MIXED | — | — |
| 2025-09-03 | Ralph Smalling | Head of Regulatory | A | — | — |
| 2025-09-03 | Thomas Zindrick | President and CEO | MIXED | — | — |
| 2025-08-29 | James L Tyree | Director | A | — | — |
| 2025-08-29 | Thomas Zindrick | President and CEO | A | — | — |
| 2025-08-29 | Joseph Cappello | Chief Technical Officer | A | — | — |
| 2025-08-29 | Yong Yu | SVP, Clinical Development | A | — | — |
| 2025-08-29 | John Thomas | Director | A | — | — |
| 2025-08-29 | John W Smither | Director | A | — | — |
| 2025-08-29 | Mary Mirabelli | Director | A | — | — |
| 2025-08-29 | Ralph Smalling | Head of Regulatory | A | — | — |
| 2025-07-02 | Eric Groen | General Counsel & Secretary | A | — | — |
| 2025-06-24 | John Thomas | Director | G | — | — |
| 2025-05-13 | Ralph Smalling | Head of Regulatory | Sell | — | — |
| 2025-05-13 | Yong Yu | VP, Clinical Trial Operations | Sell | — | — |
| 2025-05-13 | Thomas Zindrick | President and CEO | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,258,760 | — |
| — | President and CEO | 1,426,427 | — |
| — | Director | 501,193 | — |
| — | Chief Technical Officer | 318,480 | — |
| — | Chief Financial Officer | 278,906 | — |
| — | Chief Scientific Officer | 258,688 | — |
| — | General Counsel | 233,957 | — |
| — | Associate VP, Research | 139,533 | — |
| — | Director | 102,693 | — |
| — | Director | 96,483 | — |
| — | Director | 91,403 | — |
| — | Chief Financial Officer | 82,452 | — |
| — | Head of Regulatory | 67,611 | — |
| — | General Counsel | 47,621 | — |
| — | Head of Quality | 22,278 | — |
| — | Director | 9,564 | — |
| — | Vice President, Finance | 2,303 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GNLX quote page; the site-wide leaderboard is on the insider transactions hub.